Groupe d'Etude en Oncologie du Quebec

Titre	A phase 1A/B open-label master study of PF-07799544 as a single-agent and in combination with other targeted agents in participants with advanced solid tumors
Protocole ID	C4901001
ClinicalTrials.gov ID	NCT05538130
Type(s) de cancer	Tumeurs solides
Phase	Phase I
Type étude	Clinique
Médicament	PF-07799544
Institution	CENTRE UNIVERSITAIRE DE SANTE MCGILL SITE GLEN 1001 boul. Décarie , Montréal, QC, H4A 3J1
Ville	Montréal
Investigateur(trice) principal(e)	Dr Ramy Saleh
Coordonnateur(trice)	Abdul-Rahman El-Hassan 514-934-1934 poste 35161
Statut	Actif en recrutement
Date d'activation	14-02-2024
Critètes d'éligibilité	Diagnosis of advanced/metastatic solid tumor including primary brain tumor for monotherapy phase 1a dose escalation Disease progressed during/following last prior treatment and no satisfactory alternative treatment options for monotherapy phase 1a dose escalation For Substudy A and B, histological or cytological diagnosis of advanced/metastatic melanoma For Substudy A and B, measurable disease by RECIST version 1.1 For Substudy A, evidence of a BRAF V600 mutation in tumor tissue and/or blood For Substudy B, evidence of a BRAF V600 mutation or BRAF Class II alteration in tumor tissue and/or blood
Critètes d'exclusion	Brain metastasis larger than 4 cm Systemic anti-cancer therapy or small molecule therapeutics ongoing at the start of study treatment. For participants who may get binimetinib on study, history or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)

Groupe d'étude en oncologie du Québec